You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201471 - 201480 of 207728 results
  1. High Throughput Assay to Identify New Drugs Against Vivax Malaria Liver Stages

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Plasmodium vivax (Pv) is the 2nd most important human malaria parasite, causing more than 80 million cases annually, and significant severe disease and mortality that were previously unrecognized. Recent data indicate that the impact of Pv malaria on health and economies of the developing world has been dramatically underestimated. Pv is responsible for at leas ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Anionic Phospholipid-Selective PET/SPECT Agent for Infection Imaging

    SBC: MOLECULAR TARGETING TECHNOLOGIES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Although a rapid and accurate diagnosis is crucial to the management of patients suspected of bacterial infection, the currently available radiopharmaceuticals are not capable of distinguishing between sterile inflammation and bacterial infections. Our goal is to develop an infection-specific PET/SPECT radiopharmaceutical for eventual use in clinical practice. ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. Formulation of TLR 3, 7, and 8 Agonists in Conjugatable Adjuvant Lipid Vesicles

    SBC: MOLECULAR EXPRESS, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): The overall goal for this SHIFT SBIR application is to develop new, easy-to-use conjugatable adjuvant lipid vesicle (CALV) kits which contain Toll-like Receptor (TLR) agonists 3 and 7/8. Utilizing our proprietary VesiVax(R) CALV system and the Bacillus anthracis antigens, Protective Antigen (PA) and poly-3-D-glutamic acid (PGA), as model antigens, we will evalu ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Rapid Identification of Pathogenic Bacteria and Sepsis Diagnosis

    SBC: ISENSE, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Sepsis is a common and frequently fatal condition with a mortality rate that ranges from 20% to 50% for severely affected patients. It is the second leading cause of death in the U.S. among patients in non-coronary intensive care units and the 10th leading cause of death overall. It is a rapidly increasing health concern, especially for elderly, immune-compromi ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Toxoid adjuvant CRM197 production in a stable reduced genome E. coli strain

    SBC: SCARAB GENOMICS, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Scarab Genomics has developed valuable reduced-genome strains of Escherichia coli in which multiple deletions remove from the genome much unwanted and all potentially hazardous DNA. These Clean Genome(R) strains, alongwith Scarab's gene expression technology, provide a system for producing high yields of premium-quality proteins very efficiently. In this P ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Compounds Targeting Bacterial PBPs

    SBC: VENATORX PHARMACEUTICALS INC            Topic: NIAID

    DESCRIPTION (provided by applicant): This Phase I SBIR Application centers on a new class of non-??-lactam antibacterial agents that target the same biological target as the ?-lactam class of antibiotics (i.e., the Penicillin Binding Proteins, or PBPs), but with the prospect of avoiding n important determinant of cross-resistance to ?-lactams. We have identified a novel series of highly selective, ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Antimicrobial Hydrogels for Prevention of Surgical Site Infections (SSIs)

    SBC: Amicrobe, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Surgical site infections (SSIs) are a leading complication of surgery. SSIs cause patient morbidity and mortality, and place a significant burden on healthcare. Despite high standards of preventive care, wound infections are a serious problem. Surgical incisions break host defense barriers and increase microbial contamination of tissues. Biocompatible antimicro ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Targeted Dendritic Cell Activation through Multi-Adjuvant Liposomes

    SBC: MOLECULAR EXPRESS, INC            Topic: NIAID

    DESCRIPTION (provided by applicant): The overall goal of this SBIR AT application is to develop a multi-adjuvant liposomal vaccine formulation that targets dendritic cells and can be applied to our current vaccine programs. The innovation is a dual adjuvant system where VesiVax(R) lipid vesicles are formulated with a TLR9 agonist (CpG) and CD40 Ligand fused to the Company's proprietary Hydrop ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Secure Web-Based Flow Cytometry in Clinical Use and Translational Research

    SBC: CYTOBANK, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The ability of flow cytometry to measure 30 or more parameters on individual cells makes it a perfect tool for analyzing complex mixtures of cells such as peripheral blood or tumor sample from patients with various diseases. New assays have enabled researchers to measure signaling pathways inside individual cells, providing insight into the pathology of cancers ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Fast accurate ultrasensitive in vitro assay to determine BoNT potency and stability

    SBC: NESHER TECHNOLOGIES INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Botulinum Neurotoxins (BoNTs) are the most toxic substances known and classified as Category A biothreat agents. BoNTs are zinc metalloproteases that cleave and inactivate proteins involved in synaptic vesicle fusion and acetylcholine release. Therapeutic applications of botulinum toxins have increased steadily over the years requiring new and reliable assays t ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government